Who We Are‎ > ‎

Tom Nufert

Thomas H. Nufert is a Co-Founder of Nanopolymer Systems, Directors, and Vice President of Corporate Development. He is responsible for shaping the corporate development blueprint involving business plan formation, finance, business development relationships, investor liaison and anticipated business spin-offs and direction. He has worked with Steve Fowkes in various capacities for over 15 years.

Tom is a scientist/entrepreneur with more then 20 years of extensive experience in shaping, founding, financing and managing early-stage technology ventures. He is co-inventor on nine published patent applications, which draw on his diverse interdisciplinary background in bio-inorganic chemistry, physics, biochemistry, micronutrient metabolism, biochip development, endocrinology, and metabolism. These patents range from creating new chemical entities for treating insulin resistance to nanotechnology. The later involves nanochemical methods that integrate principles of chemistry, biology and physics for creating biochips for bioanalytical measurement using receptor-based binding and Raman spectroscopy (SERS).

He was Co-founder and VP of R&D for Array BioScience Corporation (Oakland, CA) during 1999-2003, a product engineering-stage company focused on universal biochip measurement tools for biomedical research, which integrated technology in the fields of nano-chemistry, receptor-based binding and Raman spectroscopy (SERS). He co-created initial research plans and created IP strategy, secured Series A funding ($200K) and positioned the company to complete a $2M (Series B) funding round.

Prior to the inception of Array BioScience he and biophyicist David I. Kreimer (formerly with Weizmann Institute of Science, Rehovot, Israel and at the time with the Department of Molecular & Cell Biology/Univ. of California Berkeley, immersed themselves in understanding the analytical chemistry of direct measurement methods and co-authored a review paper on the subject in JMBAB (June 15, 1999).

From 1998 to 2001 he was informally associated with Bruce Ames, Ph.D., at Children’s Hospital of Oakland Research Institute (CHORI) where he advanced concepts of lipid and ketone metabolism, which subsequently resulted in a paper co-authored with Theodore VanItallie M.D (Columbia University, College of Physicians and Surgeons), that was selected as Lead Paper in Nutrition Reviews Oct 2003. He primarily contributed the detailed biochemistry of the paper. The authors propose a new dietary approach to treating neurodegenerative diseases; an approach now being supported by preliminary clinical findings on Parkinson’s disease (T. VanItallie Neurology. 2005 Feb 22;64(4):728-30).

From 1986-1992 he was Founder, CEO and Chairman of Thomas Research Corporation (TRC), Hayward, CA, a pharmaceutical R&D company focused on creating new treatments for insulin resistance (metabolic syndrome) and diabetes involving newer understandings of the chromium 3+ coordination chemistry as applied to biological systems. TRC attracted a host of scientists to the company including George M. Briggs, Ph.D. (Berkeley), Henry Lardy, Ph.D. (Wisconsin), and Nobel laureates Melvin Calvin, Ph.D. (Berkeley), and Henry Taube, Ph.D. (Stanford). Over $2M of finance was raised during the difficult 1987-88 market to support a staff of 15.

In 1983-1986 he founded Thomas Laboratories (Hayward, CA) and developed Arth-Relief,™ a copper-containing topical analgesic drug and was responsible for all aspects of product and business development from product inception through regulatory affairs, analytical and validation process, distribution, marketing and sales.

From 1984 to the present, he serves as Biomedical Consultant to attorneys, physicians and their patients to enable access to advanced strategies for legal cases, disease diagnostics and disease management.

Contact information:
cell 925-639-7437

Evergreen State College, Olympia, Washington, B.A., Interdisciplinary Studies, 1975
1972-3 University of Illinois, Springfield, Illinois Campus.

Link to other publications and patent applications: TBC